XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring
6 Months Ended
Jun. 30, 2020
Restructuring And Related Activities [Abstract]  
Restructuring

13.

Restructuring

On May 23, 2019, we implemented a strategic organizational restructuring, principally to align our operations around our vaccine business and significantly curtail further investment in our immuno-oncology business. In connection with the restructuring, we reduced our workforce by approximately 80 positions, or approximately 36%, of U.S.-based personnel. Also, in connection with the restructuring, our Chief Executive Officer, also a member of the Board of Directors (the “Board”), retired from the Company and the Board, effective August 1, 2019.

During the three months ended June 30, 2019, we recognized restructuring charges of $8.8 million, of which $4.7 million was related to severance and other termination benefits and $4.1 million was related to stock-based compensation expense as a result of accelerated vesting of stock awards and the extension of exercise period of stock options. At December 31, 2019, we have completed our restructuring activities and all of restructuring costs totaling $13.4 million have been incurred.